Averna Therapeutics
Genomics & Genetic Testing · Vaccines
$170Mtotal raised · 2 rounds on record
$85Mlatest round · Venture round · Apr 2024 · 2 yr ago
4backers · Innovation Endeavors, Insight Partners
50+team · employees, estimated range
Overview
Averna Therapeutics is creating the last, great missing tool required to break through the most persistent barriers in genetic medicine.
Key facts
These are the key facts about Averna Therapeutics on Alion as of Nov 13, 2026. Averna Therapeutics is headquartered in Watertown, United States. It was founded in 2022. It has raised $170M in 2 funding rounds. The latest round is Venture - Series Unknown of $85M, announced in 2024.
- Headquarters
- Watertown, United StatesAlion company profile, updated Sep 29, 2026
- Founded
- 2022Alion company profile, updated Sep 29, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $170MSum of 2 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $85M · Apr 8, 2024SEC Form D filing · sec.gov
Funding and backers
Total raised
$170M
2 rounds on record
Latest round
$85M
Venture round · Apr 2024 · 2 yr ago
Team
51-200
employees, estimated range
Backers
4
Innovation Endeavors, Insight Partners
The money's age
Long since its last round
31 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 20
New executive Tal Zaks, Director, Executive Officer · SEC Form D
Jan 27, 2025
New executive Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer · YahooFinance
Apr 17, 2024
Board appointment Alex Harding, Director · SEC Form D
Apr 8, 2024
Raised a round Venture round $85M · SEC Form D
Apr 8, 2024
Raised a round Venture round $85M · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2024 | $85M | — | SEC Form D |
| Venture round | Apr 2024 | $85M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Averna Therapeutics Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Roy AmariglioDirectorSEC Form D
Tal Zaks M.D. Ph.D.Director, Executive OfficerSEC Form D
Thomas Barnes Ph.D.Director, Executive OfficerSEC Form D
Anat NursellaExecutive OfficerSEC Form D
Thomas BarnesDirector, Executive OfficerSEC Form D
Richard MorrisExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Enhanced Genomics
backs Nostos Genomics
Similar startupsby what they do, their industry and backers
NeoVac is creating revolutionary, unique and proprietary next-generation lipid nanoparticles.
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years…
Phenomix Sciences uses AI for precision obesity medicine integrating genetic, clinical, and biomarker data. Deliver the right intervention…
Turn your data into genetic insights and get answers for your most complex cases at scale through fast and automated HPO-driven variant…
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Enhanced Genomics is redefining how medicines are discovered by revealing the causal biology behind genetic variation. Our integrated 3D…
People
Roy Amariglio
Director
Tal Zaks M.D. Ph.D.
Director, Executive Officer
Thomas Barnes Ph.D.
Director, Executive Officer
Anat Nursella
Executive Officer
Thomas Barnes
Director, Executive Officer
Richard Morris
Executive Officer
Tal Zaks
Director, Executive Officer
Henry Chen
Director
Dylan Morris
Director
Stephen Squinto
Director
Raju Prasad Ph.D.
Director
Aaron Nelson
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Novartis Venture FundVia a fund
Innovation EndeavorsVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Insight PartnersVia a fund
812 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced that Tom Barnes, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on
Read more
Report
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert therapeutic changes into the genome, today announced the appointment of Thomas M. Barnes, Ph.D., as chief
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Watertown
United States
HQ
USA
50-200 est. staff
134 Coolidge Avenue, Watertown, MA 02472, USA
How to cite this page
Alion, "Averna Therapeutics: key facts", as of Nov 13, 2026. https://alion.io/company/averna-therapeutics
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0